Project Grant HT94252410022

This $480,990 Project Grant awarded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) aims to establish the central role of a recently identified lung cell type, "aerocytes," in regulating alveolar regeneration following lung injury. The research proposal has two key objectives: Investigate the role of aerocyte-derived R-spondin3 in lung growth and recovery using animal studies within disease-related lung injury models....

This $775,992 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells and glucocorticoids in the resolution of acute lung injury and acute respiratory distress syndrome (ARDS). The research aims to determine how glucocorticoid signaling through regulatory T cells impacts the recovery of lung structure and function following...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), has awarded a $194,740 Project Grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on establishing lung resident self-antigen-specific CD4+ regulatory T cells (Tregs) following acute tissue injury. The 5-year project, starting on Mar 1, 2025 and ending on Feb 28, 2030, aims to characterize...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $701,795 to The Trustees of the University of Pennsylvania to conduct research on lung regeneration and the impact of acute lung injury. The research aims to investigate the short- and long-term effects of viral injury on the respiratory system, utilizing advanced techniques like cell lineage tracing, single-cell analysis, and spatial mapping. Key objectives...

This federal Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), provides $761,262 to The Trustees of Columbia University in the City of New York to conduct research on using mesenchymal stromal cells to protect against acute lung injury. The key objectives of this research project are to evaluate the molecular mechanisms by which mesenchymal stromal cells attach to lung endothelium and transfer mitochondria...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $499,585 to The University of Texas Health Science Center at Tyler to conduct preclinical testing and optimization of a novel two-target fibrinolytic therapy (T2FT) for treating empyema, a severe pleural infection. The primary objectives are to: 1) Determine if concurrently inhibiting inflammation (using a TREM-1 peptide inhibitor) and the fibrinolytic system...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides funding to Aqualung Therapeutics, Corp to support research focused on developing a novel monoclonal antibody therapy (ALT-100) that targets the ENAMPT-TLR4 signaling pathway to slow the progression of idiopathic pulmonary fibrosis (IPF). The $284,699 award will be used to optimize the dosing of ALT-100...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $219,024.00 to The University of Texas Health Science Center at Tyler to test the ability of the CSP7 peptide to inhibit radiation-induced lung injury (RILI) and resolve radiation-induced pulmonary fibrosis (RIPF) in mouse models. The award aims to develop a novel peptide intervention for cancer patients undergoing thoracic radiation therapy, which can lead to acute and chronic lung...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how tissue factors in the lung alter the inflammatory response to viral infections, leading to the loss of alveolar type 2...